Gauthier O, Bouler J M, Weiss P, Bosco J, Daculsi G, Aguado E
Equipe INSERM Matériaux d'intérêt Biologique, UPRES EA 2159, Faculté de Chirurgie Dentaire, 1 place Alexis Ricordeau, BP 84215, 44042 Nantes cedex 01, France.
J Biomed Mater Res. 1999 Oct;47(1):28-35. doi: 10.1002/(sici)1097-4636(199910)47:1<28::aid-jbm4>3.0.co;2-p.
This study investigated the in vivo performance of two composite injectable bone substitutes (IBS), each with different calcium-phosphate particles granulometries [40-80 (IBS 40-80) and 200-500 microm (IBS 200-500)]. These biomaterials were obtained by associating a biphasic calcium-phosphate (BCP) ceramic mineral phase with a 3% aqueous solution of a cellulosic polymer (hydroxy-propyl-methyl-cellulose). Both materials were injected for periods of 2, 3, 8, or 12 weeks into bone defects at the distal end of rabbit femurs. Quantitative results on new bone formation, BCP resorption, and staining for tartrate-resistant acid phosphatase (TRAP) activity were studied for statistical purposes. Measurements with scanning electron microscopy and image analysis showed that the final rates of newly formed bone were similar for both tested IBS after 12 weeks of implantation. Bone colonization occurred more extensively during early implantation times for IBS 40-80 than for IBS 200-500. For the latter, BCP degradation occurred regularly throughout the implantation period, whereas it was very intensive during the first 2 weeks for IBS 40-80. Positive TRAP-stained degradation cells were significantly more numerous for IBS 40-80 than for IBS 200-500 regardless of implantation time. With the granulometry of either mineral phase, both tested IBS supported extensive bone colonization, which was greater than that previously reported for an equivalent block of macroporous BCP. The resorption-bone substitution process seemed to occur earlier and faster for IBS 40-80 than for IBS 200-500. Both tested IBS expressed similar biological efficiency, with conserved in vivo bioactivity and bone-filling ability.
本研究调查了两种复合可注射骨替代物(IBS)的体内性能,每种骨替代物具有不同的磷酸钙颗粒粒度[40 - 80(IBS 40 - 80)和200 - 500微米(IBS 200 - 500)]。这些生物材料是通过将双相磷酸钙(BCP)陶瓷矿物相与纤维素聚合物(羟丙基甲基纤维素)的3%水溶液相结合而获得的。将两种材料分别注射到兔股骨远端的骨缺损处,持续2、3、8或12周。为了进行统计分析,研究了新骨形成、BCP吸收以及抗酒石酸酸性磷酸酶(TRAP)活性染色的定量结果。扫描电子显微镜测量和图像分析表明,植入12周后,两种测试的IBS新形成骨的最终速率相似。在植入早期,IBS 40 - 80的骨定植比IBS 200 - 500更广泛。对于后者,BCP降解在整个植入期内有规律地发生,而对于IBS 40 - 80,在最初2周内降解非常剧烈。无论植入时间如何,IBS 40 - 80中TRAP染色阳性的降解细胞数量均显著多于IBS 200 - 500。无论矿物相的粒度如何,两种测试的IBS都支持广泛的骨定植,其程度大于先前报道的等效大孔BCP块。IBS 40 - 80的吸收 - 骨替代过程似乎比IBS 200 - 500更早、更快地发生。两种测试的IBS表现出相似的生物学效率,体内生物活性和骨填充能力得以保留。